The hype around the health technology assessment review and the premise of the industry's 13 'discussion papers' both reflect a fundamental misunderstanding of how it is used in decision-making simply because more technical inputs can only ever mean more reasons to say no.
More HTA is not the solution because it will just create more reasons to say 'no'
November 11, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Genomic testing to reach more patients with hard to treat cancers
September 17, 2026 - - Latest News -
Eight women named finalists for 2026 Marie Krogh Young Women in Science Prize
September 17, 2026 - - Latest News -
'Your success makes you a target and take it as a compliment'
September 16, 2026 - - Latest News -
New Zealand ranks last among wealthy nations on modern medicines access, new report finds
September 16, 2026 - - Latest News -
Young Australians badly misjudge when fertility starts to decline, new survey finds
September 16, 2026 - - Latest News -
New research points to a 'Doctor gap' holding back clinical trial participation in Australia
September 16, 2026 - - Latest News -
From constitutional promise to creaking system - the PBS at 80
September 16, 2026 - - Latest News
